is part of the Informa Markets Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
At Medlab Middle East 2022, Sansure Biotech will showcase a range of molecular and antigen diagnostics products for diseases such as COVID-19, respiratory tract diseases, HPV, STIs as well as “automated solutions” and “POCT portable molecular diagnostics systems” (iPonatic 4 Modules). Our full-scenario solutions can perfectly meet the needs of different customers and application scenarios.
Innovation allows us to implement the latest strategies to ensure that we can effectively meet customers’ expectations. Sansure has never stopped innovating since its inception. Take the scientific and technical products and services for COVID-19 diagnosis for example: we have provided innovative solutions for all scenarios in accordance with different anti-epidemic periods and different lab conditions. Since the beginning of the pandemic, Sansure has been continuously improving the COVID-19 detection program, optimizing nucleic acid detection systems. What’s more, Sansure has launched a series of new products in order to fight against the pandemic, including SARS-CoV-2 antigen, antibody and variant detection reagents. The full-scenario solutions of COVID-19 detection have been released, which have assisted more than 160 countries and regions around the world, including China, France, the UAE, the Philippines and Thailand. “Sansure Solution” for COVID-19 has become an important contributor to anti-pandemic molecular diagnostics in Europe, the Middle East, Southeast Asia and other regions.
Believing in technological innovation, we have developed various products, serving infectious disease diagnosis, cancer screening and respiratory pathogen testing. New platform development in the field of immunology reagents, NGS and rapid genetic testing will continue to strengthen our leading position globally.
At present, the COVID-19 pandemic is still severe, and the risk of new variants is high. Because of the Omicron variant, which has intensified the spread of COVID-19, pandemic prevention and control will be the main focus. Measures such as expanding the scope of testing, improving the efficiency of testing, and rapid reporting of results of testing will become mainstream in fighting against COVID-19. After the pandemic, we should not ignore the dangers from other infectious diseases, such as influenza, tuberculosis and other respiratory infectious diseases, viral hepatitis and AIDS. Sansure is committed to building the capacity of global prevention and control of major infectious diseases, drawing on our experience and assisting the world to build a healthier system.
The pandemic has taught us all an important lesson on public health concerns that people are aware of the importance of molecular diagnostics. As we all know, molecular diagnostics is the gold standard for identifying SARS-CoV-2. Based on the PCR technology, Sansure has further developed innovative platforms, which have greatly reduced the difficulty of operation, and the professionals can operate them after simple training sessions.
We always believe that technical service is crucial to our end users. During the past two years, Sansure has sent hundreds of technical engineers to many countries and regions around the world to provide technical services and training. And our service team can bring around-the-clock service when needed.
As a leading company in the field of molecular diagnostics, Sansure always adheres to the dual-wheel drive of “innovation + service” to provide top testing products and technical services to laboratories.
After over 10 years of continuous development, Sansure has formed the core value of “IShare” and has taken “innovating diagnostics for all” as its social mission.
In terms of product development, Sansure will further optimise the overall solutions of viral hepatitis test, SARS-COV-2 test, blood screening, respiratory pathogens diagnosis and other production lines, and expand the fields of infectious disease diagnostics, early tumour screening, oncology individualised medication guidance, chronic disease management, pet medical care and animal disease prevention and control, etc. We will improve the coverage of business market and accelerate the breakthrough from business market to consumer market. We will also invest more in the medical device, immunoassay and sequencing platform, towards a platform company, further enhancing organic growth drivers and outward expansion capabilities.